1 Bekker PJ, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research 2004 Jul;19(7):1059-66.
2 Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine. 2009 Aug 20;361(8):756-65.
3 Bone HG, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523.
4 Miller PD, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-229.
5 Anastasilakis AD, et al. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research. 2017 Jun;32(6):1291-1296.
6 McDonald MM, et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell. 2021 Mar 4;184(5):1330-1347.e13.
7 Fassio A, et al. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone. 2019 Jun;123:191-195.
8 Anastasilakis AD, et al. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-year Clinical Trial. Journal of Bone and Mineral Research. 2019 Dec;34(12):2220-2228.
9 Everts-Graber J, et al. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Journal of Bone and Mineral Research. 2020 Jul;35(7):1207-1215.
10 Sølling AS, et al. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. Journal of Bone and Mineral Research. 2020 Oct;35(10):1858-1870.
11 Cosman F, et al. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. J Bone Miner Res. 2022 Nov;37(11):2112-2120.
12 Everts-Graber J, et al. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone. 2021 Mar;144:115830.
13 Everts-Graber J, et al. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting. Bone. 2022 Oct;163:116498.
14 Tsourdi E, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26;dgaa756.
15 Noble JA, et al. Should denosumab treatment for osteoporosis be continued indefinitely? Therapeutic Advances in Endocrinology and Metabolism. 2021 Apr 22;12:20420188211010052.
16 Black DM, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. New England Journal of Medicine. 2020 Aug 20;383(8):743-753.
17 Everts-Graber J, et al. Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy-A Registry-Based Cohort Study. JBMR Plus. 2022 Sep 22;6(10):e10681.
18 Ferrari S, et al. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. Journal of Bone and Mineral Research. 2019, Jun;34(6):1033-1040.
19 Lyu H, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: A population-based cohort study. Ann Intern Med. 2020 Oct 6;173(7):516-526.
20 Reyes C, et al. Real-Life and RCT Participants: Alendronate Users Versus FITs’ Trial Eligibility Criterion. Calcif Tissue Int. 2016 Sep;99(3):243-9.